Email - CMS restricts coverage of disease-modifying drug

Donate

Enews from the Alzheimer's Association

Having trouble viewing this message? You may view it as a web page. You may also view e-news archives.
To prevent mailbox filters from deleting your Alzheimer's Association email communications, please add alzheimers_enews@alz.org to your address book.

24/7 Helpline: 800.272.3900

CMS restricts coverage of disease-modifying drug

The Centers for Medicare & Medicaid Services (CMS) announced that it will limit coverage of aducanumab, a Food and Drug Administration (FDA)-approved therapy that targets amyloid in the brain, to individuals enrolled in qualifying clinical trials. The Alzheimer’s Association believes people living with Alzheimer’s should have FDA-approved treatments covered by Medicare just as those facing other diseases do.

Discovery of Alzheimer’s genes could lead to treatment pathways

An additional 42 genes connected to the development of Alzheimer's, including ones tied to inflammation and the body’s immune system, have been uncovered in the largest study of genetic risk for the disease to date. Experts say the discovery will provide researchers with potential new targets for treatments, medications and lifestyle changes that might reduce Alzheimer’s risk.

Help fight Alzheimer's

Give Now

Get Involved

Your Local Community

Find a chapter here

Join our match challenge while your gift can go 2X as far

During our End Alzheimer's One-Day Match Challenge, your gift, up to $50,000, can go twice as far to provide care and support to help families facing Alzheimer’s and accelerate critical research. Don’t miss this exciting, limited-time opportunity to make 2X the impact before April 14.

More Resources:

Stages of Alzheimer's

Behaviors

Coping Strategies

Care Training


My Preferences:
Unsubscribe To stop receiving our weekly e-newsletter, simply unsubscribe.		Subscribe Was this e-newsletter forwarded to you? Subscribe to get it weekly.